CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


We found 6914 result(s)

Communication Updates

Published on: August 26, 2019
Result type: General Content

In keeping with the pCODR principle of transparency, CADTH regularly publishes pCODR Communication Updates of interest to stakeholders. CADTH also posts pCODR Drug Review Updates. You can subscribe to E-Alerts to be notified when new items are added to either page. August 22, 2019
Pharmaceutical Reviews Update — Issue 10 July 31, 201...

Axicabtagene Ciloleucel for Adults With Relapsed or Refractory Large B-cell Lymphoma

Last Updated: August 15, 2019
Result type: Reports
Product Line: Optimal Use

Axicabtagene ciloleucel is a chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and subtypes of DLBCL (e.g., primary mediastinal large B-cell lymphoma and DLBCL arising from follicular lymp...

  • Project Number: CT0002-000

Conflict of Interest

Published on: April 22, 2013
Result type: General Content

A conflict of interest is a situation in which personal, occupational, or financial considerations — either direct or indirect — may affect, or appear to affect, the objectivity or fairness of an employee, panel, or committee member, or contractor. A conflict of interest may be real, potential, or perceived in nature. In order to maintain the ob...